Literature DB >> 15462575

The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety.

John K Iskander1, Elaine R Miller, Robert T Chen.   

Abstract

The role of the health professional in supporting the national passive surveillance system is essential, as the first hint of a potential problem usually originates with the astute clinician who reports a case to the appropriate source. The investigation that resulted in the voluntary withdrawal of rotavirus vaccine was triggered by nine reports to VAERS of intussuception, eight of which had occurred within 1 week of the first dose of this vaccine. Health professionals have access to the most complete information related to adverse events experienced by their patients. Any index of suspicion that a serious event or death may be related to vaccination is reason for the health professional to submit a VAERS report. Determination of whether an event was caused by the vaccine is not a prerequisite for filing a VAERS report. When in doubt, providers should report to VAERS. VAERS solicits reports for all events temporally related to vaccination, some of which may be coincidental and some of which may merely indicate a change in the frequency of expected events. Post-marketing surveillance relies on health professionals to report suspicious events, thus improving the quality of reported data and contributing significantly to safeguarding public health. Recommendations for healthcare professionals to report to VAERS recently have been incorporated into the Standards for Pediatric Immunization Practices, which are endorsed by multiple professional organizations. Despite the limitations of spontaneous reports, VAERS provides vital information of clinical importance. The identification of signals in adverse event surveillance may initiate further investigation of potential problems in vaccine safety or efficacy, and facilitate subsequent dissemination of safety-related information to the scientific community and the public. This process begins with voluntary submission of reports of possible vaccine-associated events to VAERS by the informed and conscientious health professional.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15462575     DOI: 10.3928/0090-4481-20040901-11

Source DB:  PubMed          Journal:  Pediatr Ann        ISSN: 0090-4481            Impact factor:   1.132


  17 in total

1.  Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.

Authors:  S Elizabeth Williams; Barbara A Pahud; Claudia Vellozzi; Peter D Donofrio; Cornelia L Dekker; Neal Halsey; Nicola P Klein; Roger P Baxter; Colin D Marchant; Philip S Larussa; Elizabeth D Barnett; Jerome I Tokars; Brian E McGeeney; Robert C Sparks; Laurie L Aukes; Kathleen Jakob; Silvia Coronel; James J Sejvar; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-09-03       Impact factor: 3.641

2.  Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies.

Authors:  Jerome Ateudjieu; Beat Stoll; Anne Cecile Bisseck; Ayok M Tembei; Blaise Genton
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

Review 3.  Big Data Usage Patterns in the Health Care Domain: A Use Case Driven Approach Applied to the Assessment of Vaccination Benefits and Risks. Contribution of the IMIA Primary Healthcare Working Group.

Authors:  H Liyanage; S de Lusignan; S-T Liaw; C E Kuziemsky; F Mold; P Krause; D Fleming; S Jones
Journal:  Yearb Med Inform       Date:  2014-08-15

4.  Awareness and utilization of reporting pathways for adverse events following immunization: online survey among pediatricians in Russia and Germany.

Authors:  Susann Muehlhans; Max von Kleist; Tatiana Gretchukha; Martin Terhardt; Ulrich Fegeler; Wolfgang Maurer; Leila Namazova-Baranova; Gerhard Gaedicke; Alexander Baranov; Barbara Rath
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

Review 5.  Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).

Authors:  Tom T Shimabukuro; Michael Nguyen; David Martin; Frank DeStefano
Journal:  Vaccine       Date:  2015-07-22       Impact factor: 3.641

6.  Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations.

Authors:  Abdallah Alami; Daniel Krewski; Donald Mattison; Kumanan Wilson; Christopher A Gravel; Paul J Villeneuve; Patrick J Farrell; James A G Crispo; Santiago Perez-Lloret
Journal:  Vaccines (Basel)       Date:  2022-05-05

7.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.

Authors:  Steven Black; Juhani Eskola; Claire-Anne Siegrist; Neal Halsey; Noni MacDonald; Barbara Law; Elizabeth Miller; Nick Andrews; Julia Stowe; Daniel Salmon; Kirsten Vannice; Hector S Izurieta; Aysha Akhtar; Mike Gold; Gabriel Oselka; Patrick Zuber; Dina Pfeifer; Claudia Vellozzi
Journal:  Lancet       Date:  2009-10-31       Impact factor: 79.321

8.  Longitudinal myelitis associated with yellow fever vaccination.

Authors:  M Chaves; P Riccio; L Patrucco; J I Rojas; E Cristiano
Journal:  J Neurovirol       Date:  2009-07       Impact factor: 2.643

9.  Vaccine Safety Resources for Nurses.

Authors:  Elaine R Miller; Tom T Shimabukuro; Beth F Hibbs; Pedro L Moro; Karen R Broder; Claudia Vellozzi
Journal:  Am J Nurs       Date:  2015-08       Impact factor: 2.220

Review 10.  Safety of human papillomavirus vaccines: a review.

Authors:  Kristine K Macartney; Clayton Chiu; Melina Georgousakis; Julia M L Brotherton
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.